Reduced (±)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro

Yamini Ramamoorthy, Aiming Yu, Nina Suh, Robert L. Haining, Rachel F. Tyndale, Edward M. Sellers

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

"Ecstasy" [(±)-3,4-methylenedioxymethamphetamine or MDMA] is a CNS stimulant, whose use is increasing despite evidence of long-term neurotoxicity. In vitro, the majority of MDMA is demethylenated to (±)-3,4-dihydroxymethamphetamine (DHMA) by the polymorphic cytochrome P450 2D6 (CYP2D6). We investigated the demethylenation of MDMA and dextromethorphan (DEX), as a comparison drug, in reconstituted microsomes expressing the variant CYP2D6 alleles *2, *10, and *17, all of which have been linked to decreased enzyme activity. With MDMA, intrinsic clearances (Vmax/Km) in CYP2D6.2, CYP2D6.17, and CYP2D6.10 were reduced 15-, 13-, and 135-fold, respectively, compared with wild-type CYP2D6.1. With DEX, intrinsic clearances were reduced by 37-, 51-, and 164-fold, respectively. It was evident that CYP2D6.17 displayed substrate-specific changes in drug affinity (Km). Compounds potentially used with MDMA [fluoxetine, paroxetine, (-)-cocaine] demonstrated significant inhibition of MDMA metabolism in both human liver and CYP2D6.1-expressing microsomes. These data demonstrate that individuals possessing the CYP2D6*2, *17, and, particularly, *10 alleles may show significantly reduced MDMA metabolism. These individuals, and those taking CYP2D6 inhibitors, may demonstrate altered acute and/or long-term MDMA-related toxicity.

Original languageEnglish (US)
Pages (from-to)2111-2119
Number of pages9
JournalBiochemical Pharmacology
Volume63
Issue number12
DOIs
StatePublished - Jun 15 2002
Externally publishedYes

Fingerprint

N-Methyl-3,4-methylenedioxyamphetamine
Cytochrome P-450 CYP2D6
Metabolism
Dextromethorphan
Microsomes
Alleles
Enzyme inhibition
Pharmacogenetics
Pharmacogenomic Variants
In Vitro Techniques
Paroxetine
Fluoxetine
Enzyme activity
Cocaine
Pharmaceutical Preparations
Liver
Toxicity

Keywords

  • (±)-3,4-Methylenedioxymethamphetamine
  • Cytochrome P450 2D6
  • Drug interactions
  • Drug metabolism
  • Pharmacogenetics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Reduced (±)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. / Ramamoorthy, Yamini; Yu, Aiming; Suh, Nina; Haining, Robert L.; Tyndale, Rachel F.; Sellers, Edward M.

In: Biochemical Pharmacology, Vol. 63, No. 12, 15.06.2002, p. 2111-2119.

Research output: Contribution to journalArticle

Ramamoorthy, Yamini ; Yu, Aiming ; Suh, Nina ; Haining, Robert L. ; Tyndale, Rachel F. ; Sellers, Edward M. / Reduced (±)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. In: Biochemical Pharmacology. 2002 ; Vol. 63, No. 12. pp. 2111-2119.
@article{2252ee093c6b477eb88167c2d5385684,
title = "Reduced (±)-3,4-methylenedioxymethamphetamine ({"}Ecstasy{"}) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro",
abstract = "{"}Ecstasy{"} [(±)-3,4-methylenedioxymethamphetamine or MDMA] is a CNS stimulant, whose use is increasing despite evidence of long-term neurotoxicity. In vitro, the majority of MDMA is demethylenated to (±)-3,4-dihydroxymethamphetamine (DHMA) by the polymorphic cytochrome P450 2D6 (CYP2D6). We investigated the demethylenation of MDMA and dextromethorphan (DEX), as a comparison drug, in reconstituted microsomes expressing the variant CYP2D6 alleles *2, *10, and *17, all of which have been linked to decreased enzyme activity. With MDMA, intrinsic clearances (Vmax/Km) in CYP2D6.2, CYP2D6.17, and CYP2D6.10 were reduced 15-, 13-, and 135-fold, respectively, compared with wild-type CYP2D6.1. With DEX, intrinsic clearances were reduced by 37-, 51-, and 164-fold, respectively. It was evident that CYP2D6.17 displayed substrate-specific changes in drug affinity (Km). Compounds potentially used with MDMA [fluoxetine, paroxetine, (-)-cocaine] demonstrated significant inhibition of MDMA metabolism in both human liver and CYP2D6.1-expressing microsomes. These data demonstrate that individuals possessing the CYP2D6*2, *17, and, particularly, *10 alleles may show significantly reduced MDMA metabolism. These individuals, and those taking CYP2D6 inhibitors, may demonstrate altered acute and/or long-term MDMA-related toxicity.",
keywords = "(±)-3,4-Methylenedioxymethamphetamine, Cytochrome P450 2D6, Drug interactions, Drug metabolism, Pharmacogenetics, Pharmacokinetics",
author = "Yamini Ramamoorthy and Aiming Yu and Nina Suh and Haining, {Robert L.} and Tyndale, {Rachel F.} and Sellers, {Edward M.}",
year = "2002",
month = "6",
day = "15",
doi = "10.1016/S0006-2952(02)01028-6",
language = "English (US)",
volume = "63",
pages = "2111--2119",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Reduced (±)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro

AU - Ramamoorthy, Yamini

AU - Yu, Aiming

AU - Suh, Nina

AU - Haining, Robert L.

AU - Tyndale, Rachel F.

AU - Sellers, Edward M.

PY - 2002/6/15

Y1 - 2002/6/15

N2 - "Ecstasy" [(±)-3,4-methylenedioxymethamphetamine or MDMA] is a CNS stimulant, whose use is increasing despite evidence of long-term neurotoxicity. In vitro, the majority of MDMA is demethylenated to (±)-3,4-dihydroxymethamphetamine (DHMA) by the polymorphic cytochrome P450 2D6 (CYP2D6). We investigated the demethylenation of MDMA and dextromethorphan (DEX), as a comparison drug, in reconstituted microsomes expressing the variant CYP2D6 alleles *2, *10, and *17, all of which have been linked to decreased enzyme activity. With MDMA, intrinsic clearances (Vmax/Km) in CYP2D6.2, CYP2D6.17, and CYP2D6.10 were reduced 15-, 13-, and 135-fold, respectively, compared with wild-type CYP2D6.1. With DEX, intrinsic clearances were reduced by 37-, 51-, and 164-fold, respectively. It was evident that CYP2D6.17 displayed substrate-specific changes in drug affinity (Km). Compounds potentially used with MDMA [fluoxetine, paroxetine, (-)-cocaine] demonstrated significant inhibition of MDMA metabolism in both human liver and CYP2D6.1-expressing microsomes. These data demonstrate that individuals possessing the CYP2D6*2, *17, and, particularly, *10 alleles may show significantly reduced MDMA metabolism. These individuals, and those taking CYP2D6 inhibitors, may demonstrate altered acute and/or long-term MDMA-related toxicity.

AB - "Ecstasy" [(±)-3,4-methylenedioxymethamphetamine or MDMA] is a CNS stimulant, whose use is increasing despite evidence of long-term neurotoxicity. In vitro, the majority of MDMA is demethylenated to (±)-3,4-dihydroxymethamphetamine (DHMA) by the polymorphic cytochrome P450 2D6 (CYP2D6). We investigated the demethylenation of MDMA and dextromethorphan (DEX), as a comparison drug, in reconstituted microsomes expressing the variant CYP2D6 alleles *2, *10, and *17, all of which have been linked to decreased enzyme activity. With MDMA, intrinsic clearances (Vmax/Km) in CYP2D6.2, CYP2D6.17, and CYP2D6.10 were reduced 15-, 13-, and 135-fold, respectively, compared with wild-type CYP2D6.1. With DEX, intrinsic clearances were reduced by 37-, 51-, and 164-fold, respectively. It was evident that CYP2D6.17 displayed substrate-specific changes in drug affinity (Km). Compounds potentially used with MDMA [fluoxetine, paroxetine, (-)-cocaine] demonstrated significant inhibition of MDMA metabolism in both human liver and CYP2D6.1-expressing microsomes. These data demonstrate that individuals possessing the CYP2D6*2, *17, and, particularly, *10 alleles may show significantly reduced MDMA metabolism. These individuals, and those taking CYP2D6 inhibitors, may demonstrate altered acute and/or long-term MDMA-related toxicity.

KW - (±)-3,4-Methylenedioxymethamphetamine

KW - Cytochrome P450 2D6

KW - Drug interactions

KW - Drug metabolism

KW - Pharmacogenetics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0037096036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037096036&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(02)01028-6

DO - 10.1016/S0006-2952(02)01028-6

M3 - Article

C2 - 12110370

AN - SCOPUS:0037096036

VL - 63

SP - 2111

EP - 2119

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 12

ER -